ProStrakan taps two companies to administer REMS program for Abstral

ATLANTA — British drug maker ProStrakan Group will partner with two U.S. companies to administer its risk evaluation and mitigation strategy for a cancer pain drug.

ProStrakan said it would use RelayHealth Pharmacy Solutions’ and McKesson Specialty Care Solutions’ services to administer the REMS for Abstral (fentanyl citrate), a drug that patients can place under the tongue to treat breakthrough pain associated with cancer when they already have received and become tolerant of opioid painkillers.

“RelayHealth’s innovative connectivity technologies in pharmacies and McKesson Specialty Care Solutions’ deep REMS experience is an excellent fit for our Abstral REMS program,” ProStrakan president for global commercial operations Abid Karim said.

Login or Register to post a comment.